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ABSTRACT  24 
Zika virus (ZIKV) infection during the large epidemics in the Americas is related to 25 
congenital abnormities or fetal demise. To date, there is no vaccine, antiviral drug, or 26 
other modality available to prevent or treat Zika virus infection. Here we designed novel 27 
live attenuated ZIKV vaccine candidates using a codon pair deoptimization strategy. 28 
Three codon pair-deoptimized ZIKVs (Min E, Min NS1, and Min E+NS1) were de novo 29 
synthesized, and recovered by reverse genetics, containing large amounts of 30 
underrepresented codon pairs in E gene and/or NS1 gene. Amino acid sequence was 31 
100% unchanged. The codon pair-deoptimized variants had decreased replication fitness 32 
in Vero cells (Min NS1 >> Min E > Min E+NS1), replicated more efficiently in insect 33 
cells than in mammalian cells, and demonstrated diminished virulence in a mouse model. 34 
In particular, Min E+NS1, the most restrictive variant, induced sterilizing immunity with 35 
a robust neutralizing antibody titer, and a single immunization achieved complete 36 
protection against lethal challenge and vertical ZIKV transmission during pregnancy. 37 
More importantly, due to the numerous synonymous substitutions in the codon pair-38 
deoptimized strains, reversion to wild-type virulence through gradual nucleotide 39 
sequence mutations is unlikely. Our results collectively demonstrate that ZIKV can be 40 
effectively attenuated by codon pair deoptimization, highlighting the potential of Min 41 
E+NS1 as a safe vaccine candidate to prevent ZIKV infections.   42 
IMPORTANCE  43 
Due to unprecedented epidemics of Zika virus (ZIKV) across the Americas and the 44 
unexpected clinical symptoms including Guillain-Barré syndrome, microcephaly and 45 
other birth defects in human, there is an urgent need for ZIKV vaccine development. 46 
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Here, we provided the first attenuated versions of ZIKV with two important genes (E 47 
and/or NS1) that were subjected to codon pair deoptimization. Compared to parental 48 
ZIKV, the codon pair-deoptimized ZIKVs were mammalian-attenuated, and preferred 49 
insect to mammalian Cells. Min E+NS1, the most restrictive variant, induced sterilizing 50 
immunity with a robust neutralizing antibody titer, and achieved complete protection 51 
against lethal challenge and vertical virus transmission during pregnancy. More 52 
importantly, the massive synonymous mutational approach made it impossible to revert to 53 
wild-type virulence. Our results have proven the feasibility of codon pair deoptimization 54 
as a strategy to develop live-attenuated vaccine candidates against flavivirues like ZIKV, 55 
Japanese encephalitis virus and West Nile virus.   56 
KEYWORDS Codon pair bias, Zika, E, NS1, deoptimization, vaccine     57 
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INTRODUCTION 58 
Zika virus (ZIKV) is an enveloped virus that belongs to the Flaviviridae family (1). 59 
ZIKV was first isolated from the blood of a febrile rhesus macaque in 1947 in the Zika 60 
forest of Uganda (2), and has become a major public health risk globally driven by the 61 
current unprecedented epidemics of ZIKV across the Americas (3-5). ZIKV is usually 62 
associated with asymptomatic infections or mild febrile illness accompanied by rash 63 
conjunctivitis in human (6); however, during the large epidemics in the Americas, ZIKV 64 
infection tends to cause more severe clinical manifestations including Guillain-Barre’ 65 
syndrome (GBS), meningoencephalitis, microcephaly and other birth defects (3, 4, 7). 66 
The virus is mainly transmitted by Aedes mosquitoes, but human-to-human transmission 67 
through sexual and vertical routes have also been reported, which was different from 68 
most other flaviviruses (8, 9). The efficient transmission and comparatively limited 69 
antiviral therapeutic options have aggravated the current panic over ZIKV. To date, there 70 
is no effective licensed vaccine or antiviral treatment against ZIKV infection, although 71 
several vaccine candidates have been described including formalin inactivated vaccines 72 
(10, 11), live attenuated vaccines (12), genetic vaccines (11, 13-17), and virus-like 73 
particle (VLP) vaccines (18, 19). Therefore, new options for the development of ZIKV 74 
vaccine are needed. 75 
ZIKV genome is a single plus-strand RNA of approximately 11 kb in length and 76 
contains a single open reading frame (ORF) encoding a polyprotein that is subsequently 77 
cleaved by cellular and viral proteases into three structural proteins (C, prM, and E) and 78 
seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (20, 79 
21).The structural proteins form viral particles, and mediate attachment and entry of 80 
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ZIKV into host cells, while the nonstructural proteins are engaged in viral genome 81 
replication, virus assembly, and evasion of the host innate immune response (20, 22, 23). 82 
Specifically, the envelope (E) protein is considered as a major determinant for ZIKV 83 
pathogenesis, and is involved in modulating the viral infection cycle (24). Although not 84 
being a component of viral particles, NS1 plays an essential role in viral RNA replication 85 
as well as in host immune recognition and evasion (25, 26). Hence, the multifunctional 86 
roles of E and NS1 gene products were regarded as ideal targets for attenuation to create 87 
novel live attenuated ZIKV vaccines. 88 
Codon pair bias is interpreted as the unequal frequency in the usage of synonymous 89 
codon pairs in certain species (27-29). Based on the algorithm to quantify codon pair 90 
bias, every codon pair harbors a codon pair score (27, 28). Codon pairs with positive 91 
codon pair scores are statistically overrepresented, which may indicate that they are 92 
preferred by the organism, while the others with negative codon pair scores are 93 
underrepresented (28, 30). For instance, GCCGAA (codon pair score=-1.717) is strongly 94 
underrepresented and is used only one-seventh as frequently as GCAGAG (codon pair 95 
score=0.411), even though it contains GCC, the optimal Ala codon (27). The codon pair 96 
deoptimization, also known as synthetic attenuated virus engineering (SAVE), is a novel 97 
technique for viral attenuation by increasing the presence of underrepresented codon pairs 98 
(27, 31) In contrast, another attenuation strategy, codon deoptimization has also generated 99 
by introducing the least-preferred codons for the majority of the amino acid residues of 100 
the target genes (32, 33). Codon pair-deoptimized strains harbor identical amino acid 101 
sequences conserving the same repertoire of epitopes as the WT pathogen which may 102 
provide favorable immunogenicity and protective immunity, and contain numerous 103 
synonymous substitutions which could make the generation of virulent revertants 104 
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unlikely (34). Remarkably, the processes of codon pair deoptimization and codon 105 
deoptimization are often accompanied by the increases in CpG and UpA dinucleotide 106 
frequencies (28, 35, 36). CpG and UpA dinucleotides are rare in mammalian genes (37, 107 
38) and eukaryotic RNA viruses (39, 40), as do the codon pairs with a central xxCpGxx 108 
or xxUpAxx generally (28, 30). A raised xxCpGxx content may induce an innate immune 109 
response in certain cells, which could decrease the replicative fitness of intracellular virus 110 
(41), while the xxUpAxx abundance is deemed to reduce mRNA stability (42). To date, 111 
codon deoptimization has been used to attenuate polio virus, respiratory syncytial virus, 112 
foot-and-mouth disease virus, arenavirus, and influenza virus (32, 33, 41, 43-46), and the 113 
codon pair deoptimization strategy has also been used to generate attenuated polio virus, 114 
respiratory syncytial virus, vesicular stomatitis virus, porcine reproductive and respiratory 115 
syndrome virus, dengue virus, and influenza virus (27, 28, 30, 31, 47-49).    116 
In this study, three codon pair-deoptimized ZIKVs were designed, de novo 117 
synthesized, and recovered by reverse genetics. All the codon pair-deoptimized ZIKVs 118 
were attenuated to different extents in Vero cells (a mammalian cell line), but were not in 119 
C6/36 mosquito cells. Like their phenotype in vitro, codon pair-deoptimized ZIKVs were 120 
attenuated in vivo, and were also shown to conserve potent immunogenicity that 121 
completely protected vaccinated mice from lethal challenge and vertical virus 122 
transmission during pregnancy. These results raise the possibility of using codon pair 123 
deoptimization for the generation of novel live-attenuated ZIKV vaccine candidates.  124 
RESULTS 125 
Generation of codon pair-deoptimized ZIKVs. Because the codon pair biases 126 
between humans and mosquitoes are poorly correlated (28), the codon pair scores of the 127 
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E and NS1 genes of an Asian lineage Zika virus，SZ-WIV01 were reduced deeply 128 
according to the human codon pair bias table, but not according to the mosquito table 129 
(28). As is shown in Table 1, a total of 363 synonymous mutations were introduced in the 130 
specified E coding region, in which deoptimized human codon pair score ranged from 131 
0.0336 to -0.5741, whereas the change was minimal for the mosquito codon pair score. 132 
The same thing happened in the NS1 coding region, with the average human codon pair 133 
score being reduced from 0.0059 to -0.5162 and the change being minimal for the 134 
mosquito codon pair score. In consideration of the potential impact on virus attenuation, 135 
the increases in the frequency of XXCpGXX and XXUpAXX were also calculated. As 136 
shown in Table 2, all the codon-pair deoptimized segments possess significantly more 137 
xxCpGxx (294%–455% increase) or xxUpAxx (185%–371% increase) dinucleotides than 138 
the WT counterparts. The codon pair-deoptimized sequences presented in this paper have 139 
been submitted to GenBank: WT, MH055376; Min E, MH055377; Min NS1, MH055378; 140 
Min E+NS1, MH055379.  141 
The full-length ZIKVwt cDNA clone was constructed using reverse genetics 142 
methods (see Materials and Methods). ZIKVwt was recovered by transfection of it into 143 
Vero cells. Based on the full-length ZIKVwt cDNA clone, we designed and generated, by 144 
reverse genetics, three synthetic codon pair-deoptimized ZIKVs, named Min E, Min NS1, 145 
and Min E+NS1, in which various genome regions were subjected to codon pair 146 
deoptimization (Fig. 1). This enabled comparisons of the biological properties, 147 
pathogenicity and immunogenicity of the WT and codon pair-deoptimized viruses in vitro 148 
and in vivo.  149 
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Growth properties of codon pair-deoptimized ZIKVs in vitro. Vero cells and 150 
C6/36 cells were used to analyze the replicative properties of codon pair-deoptimized 151 
ZIKVs with each virus at the same moi of 0.01. In Vero cells, Min E as well as Min 152 
E+NS1 had a poor replication (Fig. 2A-B and Fig. 3). As for Min NS1, although its 153 
endpoint titers reached comparable levels to that of ZIKVwt, it displayed delayed 154 
replication kinetics; Min NS1 had reduced levels of viral RNA at 1 and 2 dpi (p<0.01) 155 
(Fig. 2A), and lower infectious titers at 3 and 4 dpi (p<0.01) (Fig. 2B) compared with WT 156 
virus. In addition, the average size of infectious foci decreased in the order WT, Min 157 
NS1, Min E and Min E+NS1 in Vero cells (Fig. 2G). These results indicated that the 158 
replication of the codon pair-deoptimized variants in Vero cells dramatically decreases 159 
(replication fitness: Min NS1 >> Min E > Min E+NS1). 160 
In C6/36 cells, all of the codon pair-deoptimized viruses as well as ZIKVwt reached 161 
the maximum viral loads of >2×1010 copies/ml at 8dpi (Fig. 2C). Compared with 162 
ZIKVwt, Min E+NS1 even displayed enhanced RNA replication kinetics before 4dpi 163 
(Fig. 2C), although there were no significant differences. Immunostaining focus assay 164 
was carried out to determine the infectious titers. The maximal titers of Min NS1 and Min 165 
E between 7 and 8 dpi were comparable to that of the WT virus, however, they displayed 166 
delayed replication kinetics. Min NS1 had lower infectious titers at 1, 3 and 4 dpi 167 
(p<0.05) (Fig. 2D), and Min E had reduced level of infectious titers at 1, 3, 4, 5 and 6 dpi 168 
(p<0.05) (Fig. 2D). The infectious titers of Min E+NS1 decreased stepwise at all time 169 
points (p<0.05) (Fig. 2D). 170 
Next, multipassage analysis was performed to test the passage stability of ZIKVs. 171 
Both ZIKVwt and Min NS1 reached high viral loads (Fig. 2E) and were capable of 172 
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developing infectious foci in Vero cells (Fig. 2F) from P1 to P5. Min E as well as Min 173 
E+NS1 was nonviable in Vero cells by the fourth passage and the second passage, 174 
respectively (Fig. 2E-F). 175 
Diminished virulence of codon pair-deoptimized ZIKVs in AG6 mice. An AG6 176 
mouse model was used to evaluate the diminished virulence of codon-pair deoptimized 177 
ZIKVs. Four-week-old AG6 mice were infected with different doses of ZIKVwt or codon 178 
pair-deoptimized ZIKVs through the i.p. route. Under our experimental conditions, 179 
ZIKVwt was highly virulent in these AG6 mice, with an LD50 of 1.78 PFU. Min NS1 180 
was slightly attenuated in mice with a ~1.7-fold increase in LD50 compared with 181 
ZIKVwt (Table 3). Dramatic attenuations were observed with Min E and Min E+NS1, 182 
revealing ~1000-fold and ~2000-fold increases in MLD50, respectively, compared with 183 
ZIKVwt (Table 3). The order of attenuations in the animals (Min E+NS1 >Min E >> Min 184 
NS1) was consistent with the order of attenuations in tissue culture cells. 185 
Comparative analysis of pathogenicity. AG6 mice were infected with 100IFU of 186 
either ZIKVwt or codon pair-deoptimized ZIKVs, and monitored for 28 days for weight 187 
loss (Fig. 4A), and mortality (Fig. 4B). Mice were also periodically euthanized to perform 188 
virus detection in various organs (at day 3 and 7dpi) (Fig. 5, 6A-B) and sera (at 3 and 189 
6dpi) (Fig. 6C). As expected, codon pair-deoptimized ZIKVs showed levels of 190 
pathogenicity different from those for ZIKVwt. Mice infected with Min E+NS1 shared 191 
comparable kinetics of weight gain with that of mock-treated mice (Fig. 4A), and all 192 
survived (Fig. 4B). In contrast, the survival rates of ZIKVwt, Min NS1 and Min E group 193 
were 0%, 16.7% and 83.3%, respectively. Immunohistochemistry (IHC) staining with 194 
brain tissue sections showed a wide distribution of E protein in mice infected with WT 195 
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virus, in contrast, it is difficult to detect the distribution of E protein in mice infected with 196 
Min E+NS1 virus (Fig. 5).  197 
The pathogenicity and virus load in sera as well as in infected organs are usually 198 
positively correlated (12, 30), thus, viral titers in sera, heart, liver, spleen, lung, kidney, 199 
brain, testes, uterus, ovary, eye, intestine and muscle were measured by qRT-PCR (Fig. 200 
6A and 6C), and immunostaining focus assay (Fig. 6B). Min E+NS1 was nonviable in all 201 
the tested organs except for spleen. The mean viral load of Min E+NS1 infected spleens 202 
was 10
2.17
 copies/μg total RNA at 3 dpi, which was at least three orders of magnitude less 203 
than that in their WT infected counterparts (p<0.05), and was reduced to 101.28 copies/μg 204 
total RNA at 7 dpi. The supernatants (homogenized Min E+NS1 infected spleens) were 205 
not capable of developing infectious foci in Vero cells (Fig. 6B). In contrast, in ZIKVwt-206 
infected animals, viral RNA was widespread in all the tested organs up to 7 dpi (Fig. 6A), 207 
which ultimately resulted in the death of all the remaining animals by 9 dpi (Fig. 4B).     208 
Immunogenicity and efficacy of codon pair-deoptimized ZIKVs in AG6 mice. 209 
To evaluate whether codon pair-deoptimized ZIKVs immunization elicited a B cell-210 
mediated humoral immunity, sera were collected 28 days postvaccination through the 211 
retro-orbital sinus, and titers of ZIKV-specific neutralizing antibodies (NAb) were 212 
measured by the PRNT50 assay. Mice infected with the WT or codon pair-deoptimized 213 
viruses were found to have comparable neutralizing antibody titers against the WT virus, 214 
whereas the control mice did not develop a detectable PRNT50 titer (PRNT50<10) (Fig. 215 
7A). To evaluate cellular immune responses in AG6 mice, on day 28 postimmunization, 216 
ZIKV-specific T cells from the spleen were restimulated with heat-inactivated WT virus 217 
in vitro, and analyzed by an IFN-γ ELISpot assay. The results showed that the average 218 
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IFN-γ levels secreted from the Min E+NS1-immunized group were significantly higher 219 
than that of the mock-immunized group (p<0.01) (Fig. 7B).  220 
The mice were then challenged with 104 PFU of WT virus intraperitoneally, 221 
representing an approximately 5500-fold MLD50 of ZIKVwt. All vaccinated animals 222 
survived without detectable peripheral viremia and any signs of disease (weight loss, 223 
ruffled fur, hindlimb paralysis, hunched posture, or lethargy) through day 14 (Fig. 8A-C), 224 
whereas the sham-vaccinated mice produced a mean viremia of (5.2 ± 4.0) × 108 225 
copies/ml on day 3 after challenge (Fig. 8C) and died by 10 days after challenge (Fig. 226 
8B). Furthermore, high titers of neutralizing antibodies in challenged mice were also 227 
detected (Fig. 8D). Taken together, a single-dose vaccination of the Min E+NS1 virus can 228 
elicit a robust immune response that fully protects AG6 mice against a subsequent lethal 229 
challenge. On day 28 after challenge, we measured the neutralization titers of the mouse 230 
sera again; notably, the postchallenge neutralization titers were equivalent to the 231 
prechallenge neutralization titers 232 
To determine if Min E+NS1 immunization could protect pregnant AG6 mice, we 233 
mated immunized AG6 female mice with 8-week-old naïve AG6 male mice at day 32 234 
post immunization and challenged the pregnant mice with 104 PFU of WT virus at 235 
embryo day 6 (E6) (Fig. 9A). As expected, high titers of neutralizing antibodies in 236 
pregnant mice were detected at day 1 before challenge (Fig. 9B). Following WT 237 
challenging, Min E+NS1 immunized had no signs of disease (weight loss, ruffled fur, 238 
hindlimb paralysis, hunched posture, or lethargy) throughout the experiment. PBS-239 
immunized mice developed high levels of maternal viremia, however, Min E+NS1 240 
immunized mice had no detectable maternal viremia (Fig. 9C). All PBS-immunized mice 241 
died without delivery, in contrast, all Min E+NS1 vaccinated dams successfully delivered 242 
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the healthy pups at term with normal viability (Fig. 9D). Modest low levels of maternal 243 
neutralization antibody were even detected in the sera of pups at the 21th day after birth 244 
(Fig. 9D). Collectively, preconception maternal immunity induced by Min E+NS1 245 
immunization efficiently protected AG6 mice during pregnancy, and prevented viral 246 
transmission to the fetus.  247 
DISCUSSION 248 
We have investigated the strategy of codon pair deoptimization as a means to 249 
develop novel attenuated versions of ZIKV, a pathogenic virus that caused GBS, 250 
meningoencephalitis, microcephaly and other birth defects in human (3, 4, 7). Viruses 251 
harboring deoptimized codon pairs in the E gene, NS1 gene, and E+NS1 gene were 252 
designed, rescued, and proven to be attenuated to different extents in vitro and in vivo. It 253 
should be pointed out that the most attenuated Min E+NS1 virus possessed potential to 254 
the generic development of live attenuated vaccines that produced robust 255 
immunogenicity, provided complete protection against a lethal challenge of ZIKV, 256 
protected AG6 mice during pregnancy, and prevented viral transmission to the fetus with 257 
a single dose.  258 
As far as we know, several live-attenuated ZIKV vaccines have been reported (12, 259 
50). Shan et al has generated a recombinant live-attenuated ZIKV vaccine candidate by 260 
deletion of 10-nts in the viral 3’-UTR by reverse genetics (12), while Li et al develops 261 
and characterizes a recombinant chimeric ZIKV vaccine candidate expressing the prM-E 262 
proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-263 
14-2 as the genetic backbone (50). Using strategy of codon pair deoptimization, our 264 
attenuated Min viruses express identical whole protein sequences conserving an intact 265 
 o
n
 M
arch 5, 2020 at ST G
EO
RG
E'S LIBRARY
http://jvi.asm.org/
D
ow
nloaded from
 
antigenic repertoire. Moreover, due to the large number of mutations introduced, these 266 
attenuated Min viruses are unlikely to develop virulent revertants through gradual 267 
nucleotide sequence mutations.  268 
Several mechanisms appeared to be related to the attenuation in ZIKV Min variants 269 
caused by rare codon pairs. The major effect of codon pair deoptimization should be 270 
decreased efficiency of translation in a context-dependent manner (27, 30, 32). A string of 271 
“rare” codon pairs compound the difficulties of reading through by the ribosome, 272 
resulting in less precursor proteins per mRNA. Other parameters coordinated with the 273 
translation elongation rate, such as ribosomal stalling, premature dissociation of the 274 
translation initiation complex, protein processing, folding, and/or stability, may also be 275 
involved (28, 33, 51). Additionally, the increase of CpG and UpA dinucleotides can also 276 
play important roles in RNA virus attenuation (28, 35, 36, 52, 53). Mammalian genomes 277 
and eukaryotic RNA viruses exhibit marked CpG/UpA suppression (37-40). The raised 278 
dinucleotide composition may induce an innate immune response in host cells (41, 54), 279 
and/or reduce mRNA stability (42). The recoded segments with rare codon pairs are 280 
generally associated with an enrichment of CpG and UpA dinucleotides (28, 30, 41, 43, 281 
44). In agreement, we found that all the codon pair-deoptimized segments possess 282 
significantly more xxCpGxx or xxUpAxx dinucleotides than the WT counterparts. Codon 283 
pair bias has been suggested to be a direct consequence of CpG/UpA dinucleotide bias 284 
(55), and the rise of CpG/UpA dinucleotides may be a key genetic contributor to virus 285 
attenuation by codon pair deoptimization (56), although this has been disputed (28, 57). 286 
Another finding is that the effect of codon pair usage or dinucleotide frequencies on 287 
translation is minor or nonexistent (43, 44, 52, 56), which warrants further investigation. 288 
In conclusion, it is difficult to distinguish the two effects (the increased CpG and UpA 289 
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dinucleotides or the increased frequency of disfavored codon pairs) that mediate the 290 
attenuation in ZIKV Min variants in this study.  291 
Each of the codon pair-deoptimized ZIKVs replicated less efficiently in Vero cells 292 
than the WT virus. Min E+NS1 was the most restricted codon pair-deoptimized mutant, 293 
exhibited the smallest infectious foci (Fig. 2G), the slowest replication kinetics, and the 294 
lowest peak titer (Fig. 2A-B), informing that it involves an “additive” relationship of the 295 
effect of recoded genomes, with significantly more rare codon pairs, as found with 296 
poliovirus (27), or significantly more CpG/UpA dinucleotides than those in Min E and 297 
Min NS1 (41, 42, 54). Min NS1 was less restricted in Vero cells than Min E. The 298 
seemingly counterintuitive result may be explained by the amount of codon pair changes 299 
introduced in the corresponding segments or inappropriate molar ratios of proteins 300 
relative to mRNAs, and implied that the suboptimal of NS1 could be tolerated to some 301 
extent. A key result was the observation that all the three codon pair-deoptimized ZIKVs 302 
replicated more efficiently in C6/36 cells, when compared with Vero cells (Fig. 2). The 303 
alteration of cell tropism was due to the introduction of hundreds of underrepresented 304 
human codon pairs. Because there was a poor correlation between humans and 305 
mosquitoes codon pair preference, the accumulation of underrepresented human codon 306 
pairs would not drift the cumulative codon pair score too far according to the insect table 307 
(28). One of the potential benefits is practicability of launching platform for high-yield 308 
production of attenuated ZIKV vaccine in insect cell systems, such as Sf9 and Sf21 cell 309 
lines. Although the raised CpG/UpA dinucleotide composition profoundly reduced the 310 
replication ability of RNA virus in mammalian cells, it is uncertain whether this is also 311 
true in mosquito cells. Therefore, the fact that codon pair-deoptimized ZIKVs prefer 312 
mosquito to mammalian cells may not be associated with the differences in sensing 313 
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CpG/UpA in the deoptimized viruses compared to WT virus.    314 
Mice deficient in the type I and type II IFN (IFN α/β/γ) receptors are extremely 315 
susceptible to ZIKV infection and display severe disease signs including hind limb 316 
weakness, paralysis, and death, which provide a platform for identifying determinants of 317 
ZIKV virulence and testing the efficacy of antivirals and vaccines (8, 58-60). Thus, AG6 318 
mice lacking the type I and type II IFN (IFN α/β/γ) receptors were used in the study. As 319 
expected, diminished virulence was clearly determined in the codon pair-deoptimized 320 
variants (Table 3), revealing ~1.7-fold (Min NS1), ~1000-fold (Min E), and ~2000-fold 321 
(Min E+NS1) increases in MLD50 compared with WT virus. We hypothesize that this 322 
observation is related to viral attenuation in tissue culture cells, although viral attenuation 323 
in tissue culture cells do not (necessarily) translate to that in animals (28). It is known that 324 
ZIKV was associated with microcephaly, and caused testis damage (leading to male 325 
infertility in mice) (7, 61, 62). In immunocompromised mouse model, ZIKV was 326 
widespread in all the tested tissues including brain and testis (58, 59), which was also 327 
present in our work (Fig. 6A). By contrast, Min E+NS1 was nonviable in all the tested 328 
organs (the supernatant of homogenized spleens were not capable of developing 329 
infectious foci, in spite of low-level detection of viral RNA). The observation suggested 330 
that the risk of brain and testis damage is negligible. Despite high attenuation of Min 331 
E+NS1 in the host, it induced high levels of neutralizing antibodies and IFN-γ in mice, 332 
and conferred protection against lethal challenge with WT virus. In addition, 333 
preconception maternal immunity induced by Min E+NS1 immunization is sufficient to 334 
protect pregnant AG6 mice and their fetuses (Fig. 9). We hypothesize that the strong 335 
protection was ascribed to that our codon pair-deoptimized viruses obtained repertoire of 336 
epitopes identical to that of WT virus (amino acid sequence is 100% preserved). To data, 337 
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Min E+NS1 is the first attenuated version of flavivirus with two important genes that 338 
were subjected to codon pair deoptimization simultaneously, maintaining a balance 339 
between efficacy and safety.   340 
In summary, we describe the first large-scale recoding of ZIKV, a flavivirus that 341 
belongs to a large family of mosquito-borne human pathogens. Min E+NS1 displayed the 342 
potential to develop into a promising live-attenuated vaccine candidate. Results from this 343 
study demonstrated the feasibility of rapid attenuation of ZIKV through the codon pair 344 
deoptimization strategy. The unparalleled advantage of the codon pair deoptimization 345 
strategy is that reversion to wild-type virulence is unlikely due to numerous synonymous 346 
substitutions without changing the amino acid sequence (34, 43). Thus, the codon pair 347 
deoptimization strategy would add the safety to the features of live attenuated viruses, 348 
which has a broad application in the development of vaccines for flavivirus and other 349 
important viruses.  350 
MATERIALS AND METHODS 351 
Ethics Statement. All experiments involving animals have been reviewed and 352 
approved by the Animal Care Committee of Wuhan Institute of Virology (Permit 353 
Number: WIVA07201603), in accordance with the animal ethics guidelines of the 354 
Chinese National Health and Medical Research Council (NHMRC).  355 
Cells. African green monkey kidney epithelial cells (Vero; CCL-81; ATCC) were 356 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Darmstadt, 357 
Germany) containing 10% fetal bovine serum (FBS; Life Technology, Australia), 100 358 
U/ml penicillin and 100 μg/ml streptomycin, and maintained in 5% CO2 at 37°C. Aedes 359 
albopictus C6/36 cells (C6/36; CRL-1660; ATCC) were maintained in RPMI medium 360 
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1640 (Gibco, Carlsbad, CA, UK) containing 10% FBS in 5% CO2 at 28°C. 361 
Design of Codon Pair-Deoptimized Sequences. E and NS1 genes were re-encoded 362 
by rearranging existing synonymous codons to minimize the cumulative codon pair 363 
scores according to the human codon pair bias table (27). The RNAfold software (63) 364 
was used to maintain the free energy of the folding of the RNA within a narrow range and 365 
to avoid large changes in secondary structure of the customized RNA as a consequence of 366 
codon re-arrangement. The mutated viral RNA segments were then synthesized 367 
commercially (Beijing Tsingke Biotech Co., Beijing, China).   368 
Construction of ZIKV infectious clones (ICs). The Asian-lineage strain SZ-369 
WIV01 was obtained from China Centre for General Virus Culture Collection 370 
(CCGVCC) (64). To generate the infectious cDNA of ZIKVwt, viral RNA was extracted 371 
from the parental virus by using TRIzol Reagent (TaKaRa, Dalian, China), and reverse 372 
transcribed by using PrimeScriptTM RT reagent kit (TaKaRa, Dalian, China) according to 373 
the respective manufacturers’ instruction. Five PCR fragments covering the complete 374 
viral genome of ZIKV were amplified from the cDNA reverse transcribed. PCR fragment 375 
1 containing nt 1-1590 of the genome was fused with CMV promoter and cloned into the 376 
low-copy-number plasmid pACYC177 at the KpnI and XhoI sites, yielding the subclone 377 
A. PCR fragment 2 containing nt 1532-3129, the beta-globin intron (nt. 857–989 in 378 
HaloTag CMV-neo vector pHTN, GenBank access JF920304), and PCR fragment 3 379 
containing nt 3130-5309 were overlapped and cloned into pACYC177 at the AvrII and 380 
XhoI sites, yielding the subclone B. The previous study (65) provided some clues for the 381 
insertion site of the intron. PCR fragment 4 containing nt 5291-8588 was cloned into 382 
pACYC177 at the Cla I and Xho I sites, yielding the subclone C. PCR fragment 5 383 
containing nt 8545-10942, hepatitis D virus ribozyme (HDVr) sequence, and SV40 polyA 384 
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were overlapped and cloned into pACYC177 at the SfiI and XhoI sites, yielding the 385 
subclone D. The four subclones were assembled step-by-step into a full-length infectious 386 
cDNA clone of ZIKVwt-FL as shown in Fig 1.  387 
To generate the ICs of codon pair-deoptimized ZIKVs, the codon pair-deoptimized 388 
cassette (see above) was synthesized de novo, overlapped with flanking regions at either 389 
end and cloned into ZIKVwt-FL at the KpnI and ClaI sites, yielding ZIKV Min E-FL, 390 
ZIKV Min NS1-FL, and ZIKV Min E+NS1-FL, respectively (The designation “Min” 391 
signifies that genes were designed with minimized human codon pair score in this 392 
article). Before their transfection, all the ICs were verified using a restriction map and 393 
complete sequencing.  394 
Rescue of infectious viruses and stock production. ICs were transfected into a 35 395 
mm culture dish containing 80-90% confluent monolayers of Vero cells by lipofectamine 396 
3000 (Life Technologies) in Opti-MEM (Life Technologies). The supernatant was 397 
harvested at 7 days post transfection (dpt, 4dpt for ZIKVwt), clarified by centrifugation 398 
and stored at -80°C. 399 
Each virus was amplified in C6/36 cells with a multiplicity of infection (moi) of 1 in 400 
a 100 mm culture dish. Viral supernatants were harvested at 7 days post infection (dpi), 401 
clarified by centrifugation, aliquoted, and stored at -80°C. The nucleotide identities were 402 
confirmed by sequencing.   403 
Virus growth kinetics. Sub-confluent (80%) cells in 100 mm culture dishes were 404 
infected at a moi of 0.01 in a volume of 2ml. After 1.5 h incubation at 37°C, cells were 405 
washed twice with 4ml of phosphate-buffered saline (PBS), and 8ml DMEM with 2% 406 
FBS (for Vero cells) or RPMI 1640 with 2% FBS (for C6/36 cells) was added. 800μL of 407 
cell supernatants were sampled at different time points post-infection, clarified by 408 
 o
n
 M
arch 5, 2020 at ST G
EO
RG
E'S LIBRARY
http://jvi.asm.org/
D
ow
nloaded from
 
centrifugation, aliquoted and stored until use. The virus particles were determined by 409 
real-time PCR (qRT-PCR), and infectious titers of the viruses were quantitatively 410 
analyzed using immunostaining focus assay. 411 
Multipassage analysis. Each virus was passaged on Vero cells for five rounds. The 412 
virus derived from ZIKV ICs-transfected Vero cells was defined as the parental P0 virus 413 
and used for passaging. At each passage, a calculated moi of 0.01 was used to infect 35 414 
mm culture dishes of sub-confluent (80%) cells. After 1.5 h incubation at 37°C, cells 415 
were washed three times with PBS, and 2ml DMEM with 2% FBS was added. At 4 dpi, 416 
viral supernatants were harvested, clarified, aliquoted, determined by qRT-PCR and 417 
immunostaining focus assay, and transferred to new 35 mm culture dishes containing 418 
naïve Vero cells. It should be noted that 10μl non-diluted stock solution of Min E and 419 
Min E+NS1 were used in P2-P5 passages.  420 
Plaque assay and immunostaining focus assay. Virus titrations of ZIKVwt were 421 
determined with a plaque assays expressed as plaque forming units (PFU/ml). Briefly, 422 
Vero cells at 80% confluence in 24-well plates were inoculated with 100μl of 10-fold 423 
serial dilutions of viral samples in serum free DMEM. After 1.5 h incubation, 1ml of 424 
1.25% methylcellulose containing 2% FBS was added into each well. After incubation for 425 
4 days, cells were fixed with 4% buffered formalin, and stained with 0.5% crystal violet. 426 
Plaque morphology and numbers were recorded after rinsing the plates with deionized 427 
water.  428 
Immunostaining focus assay was carried out following a previously described 429 
protocol (12) with modifications. In brief, Vero cells at 80% confluence in 24-well plates 430 
were inoculated with 100μl of 10-fold serial dilutions of viral samples. After 1.5 h 431 
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incubation, 1ml of 1.25% methylcellulose containing 2% FBS was added into each well. 432 
Cells were incubated at 37 °C for 7 d before being fixed in methanol–acetone (1:1) 433 
fixation solution. After fixation, the cells were incubated with ZIKV-specific HMAF, 434 
followed by incubation with goat anti-mouse IgG conjugated with horseradish peroxidase 435 
(HRP) as a secondary antibody. Finally, viral foci were detected by the addition of DAB 436 
(3, 3 -diaminobenzidine) HRP substrate, following the manufacturer’s instructions 437 
(Enhanced HRP-DAB kit, Tiangen, China). 438 
Indirect immunofluorescence assays (IFA). The cells infected with ZIKVs were 439 
washed once with phosphate-buffered saline (PBS) and fixed by cold (-20°C) 5% acetic 440 
acid in acetone for 15 min at room temperature (RT). The fixed cells were washed with 441 
PBS three times and incubated with a 4G2 mouse monoclonal antibody (mAb) that is 442 
cross-reactive with flavivirus E protein (ATCC) (diluted 1:200) for 1 h. After three rinses 443 
with PBS, the cells were incubated with goat anti-mouse IgG conjugated to FITC 444 
(Proteintech, Wuhan, China) at a 1:200 dilution with PBS at RT for 1h. After three rinses 445 
with PBS, cell nuclei were stained with Hoechst 33258. The fluorescent signal images 446 
were taken with a NIKON fluorescence microscope (Tokyo, Japan).  447 
Animal Immunization. AG6 mice deficient in type I and II interferon (IFN α/β/γ) 448 
receptors were gifts from Qibin Leng (Institute Pasteur of Shanghai, Chinese Academy of 449 
Sciences), and were bred in specific-pathogen-free conditions in the Animal Resource 450 
Center at the Wuhan Institute of Virology, Chinese Academy of Sciences. 4-week-old 451 
AG6 mice were infected with 104, 103, 102, 101, or 100 PFU WT or mutant viruses 452 
through intraperitoneal (ip) injection. PBS was injected into the mock-infected mice 453 
through the same route. The clinical course of the viral infection was monitored by 454 
survival, weight loss, and disease symptoms. The lethal dose 50% (LD50) for each 455 
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ZIKVs was determined using the method of Reed and Muench (66). On 3 and 6 dpi, to 456 
measure viremia, serum samples were collected from anesthetized mice and clarified by 457 
centrifugation for 5 minutes at 3000 g. On 3, 7 14, and 28dpi, heart, liver, spleen, lung, 458 
kidney, brain, testes, eye, ovary, uterus, intestine and muscle of the immunized mice were 459 
removed, weighed and homogenized with zirconia beads in 1ml of TRIzol Reagent. 460 
Then, quantification of viral load in samples was performed using qRT-PCR. On 28 dpi, 461 
the immunized mice were challenged through the i.p. route with 104 IFU of ZIKVwt, and 462 
measured for viremia on day 2 after challenge. On day 14 after challenge, all the mice 463 
were anesthetized, bled for the titration of neutralize antibody, and sacrificed. 464 
Quantitative real-time RT-PCR assays. Total RNA was extracted from cell 465 
supernatants, sera or organs using TRIzol Reagent, and reverse transcribed by using 466 
PrimeScriptTM RT reagent kit. A universal pair of primers (67) (forward primer, 467 
AARTACACATACCARAACAAAGTG, and reverse primer 468 
TCCRCTCCCYCTYTGGTCTTG) was used to amplify the region of 9378-9479 in the 469 
NS5 gene which is preserved in all virus strains. All quantitative real-time PCR (qRT-470 
PCR) assays were performed with SYBR Green Master Mix (Bio-Rad) on the CFX96 471 
touch real-time PCR detection system (Bio-Rad). Cycling conditions were as follows: 472 
95°C for 3 min, followed by 40 cycles of 95°C for 10 sec, 55°C for 10 sec, and 65°C for 473 
45 sec. The ZIKVwt NS5 gene was utilized as a standard and was cloned into pGEM-T 474 
(Promega, WI, USA). Log dilutions of the DNA standard were included with each RT-475 
PCR assay. Virus concentration was determined by interpolation onto the curve made up 476 
of 10-fold serial dilutions of the standards.   477 
Immunohistochemistry. Tissues were fixed in 4% formaldehyde at 4 °C for 24h 478 
and embedded in paraffin. For IHC, the paraffin-embedded tissues were sectioned at a 479 
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thickness of 5 µm and mounted on slides. After being heated at 60 °C for 1 h, the slides 480 
were deparaffinized with xylene, and were then cleared with alcohol. After antigen 481 
retrieval, the sections were incubated with an anti-ZIKV envelope (E) protein monoclonal 482 
antibodies (mAb) (BioFront Technologies, Fl, USA, 1:100 dilution) overnight at 4 °C. 483 
Following incubation overnight with the antibodies, a goat anti-mouse IgG conjugated 484 
with HRP was applied to each slide. Visualization was acquired with the DAB reagent 485 
(DAKO, Envision System kit). The sections were also stained with hematoxylin and 486 
eosin. Images were acquired by the whole-slide digital Pannoramic scanner (3D-Histech, 487 
Budapest, Hungary)  488 
PRNT50. 50% Plaque Reduction Neutralization Test (PRNT50) was developed for 489 
measuring ZIKV-specific neutralizing antibodies according to a previously described 490 
protocol (14) with modifications. Briefly, heat-inactivated serum samples were two-fold 491 
serially diluted, and incubated with 100 PFU ZIKVwt at 37°C for 1.5 h. Then, the virus–492 
serum mixture (200 μl) was added to Vero cells at 80% confluence in 12-well plates. 493 
After incubation at 37°C for 1.5h, 1.25% methyl cellulose overlay was added and plates 494 
were incubated for 4 days at 37 °C in 5% CO2. Then, the cells were fixed with 4% 495 
formalin and stained with 0.5% crystal violet. Plaque morphology and numbers were 496 
recorded after rinsing the plates with deionized water. PRNT50 titer was expressed as the 497 
reciprocal of the highest dilution of each serum sample that caused a 50% reduction in the 498 
plaque number relative to the control samples. Samples with titer of ≥10 were considered 499 
as seropositive.  500 
ELISPOT assay. The splenocytes were isolated by mouse lymphocyte separation 501 
medium (DAKEWEI, Beijing China) on 28 dpi, and adjusted to a concentration of 5×106 502 
cells/ml in complete RPMI-1640 medium. The production of IFN-γ was measured using 503 
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an ELISPOT assay according to the manufacturer’s instructions (DAKEWEI). Briefly, 504 
96-well PVDF plates (Millipore, Bedford, MA) were pre-coated with anti-mouse IFN-γ. 505 
Then, 100μl of lymphocytes was added to the wells in triplicate, stimulated with heat-506 
inactivated ZIKV (106IFU/well), along with RPMI 1640 medium alone (as negative 507 
control) or ConA (5μg/ml, Sigma, positive control). Following the 20 h incubation at 508 
37°C, the lymphocytes were removed, and 100 μl of biotinylated anti-mouse IFN-γ was 509 
added and incubated at 37°C for 1 h. Following washing, the plate was incubated with 510 
properly diluted Streptavidin-HRP conjugate solution at 37°C for 1 h. Finally, 100 μl of 511 
AEC substrate solution was added and incubated at RT for 25 min in the dark. The plate 512 
was stopped by washing with demineralized water, air-dried and read using an ELISPOT 513 
reader (Bioreader 4000; Bio-sys, Germany). The numbers of spot-forming cells (SFC) per 514 
5 × 105 cells were calculated. Medium backgrounds were consistently <10 SFC per 515 
5 × 105cells. 516 
Statistical Analysis. The Student’s t-test and ANOVA test were used to analyze all 517 
the virologic and immunologic data if there were significant differences (p < 0.05). The 518 
statistical analyses were performed in IBM SPSS Statistics v18.0 (Chicago, IL, USA). 519 
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Figure legends 721 
Fig 1. Construction of the infectious cDNA clone of ZIKVwt and generation of 722 
codon pair-deoptimized ZIKVs. 723 
(A) The strategy for constructing the full-length cDNA clone of ZIKVwt. Four cDNA 724 
fragments from A to D that cover the complete ZIKV genome were synthesized from 725 
viral RNA using RT-PCR, and sequentially cloned into the plasmid pACYC177 to form 726 
the full-length cDNA clone of ZIKV (ZIKVwt-FL). CMV promoter, HDVr/SV40 polyA, 727 
and the position of relevant restriction sites are shown. (B) Gene maps of the codon pair-728 
deoptimized ZIKVs Min E, Min NS1, and Min E+NS1. Codon pair-deoptimized genes 729 
are shown as white boxes; WT E gene is shown as orange box; WT NS1 gene is shown as 730 
blue box. Restriction sites (KpnI and ClaI) used for the constructions are indicated. 731 
Fig 2. Replication of WT and codon pair-deoptimized ZIKVs in cell culture.  732 
Vero cells (A and B) or C6/36 cells (C and D) were infected with viruses at an moi of 733 
0.01. Viral loads were determined by qRT-PCR (A and C), and virus titers were measured 734 
by immunostaining focus assay on Vero cells (B and D). (E and F) Growth properties of 735 
viruses were determined by passaging them on Vero cells at an moi of 0.01. (G) Plaque-736 
size phenotype on Vero cells of virus variants, visualized by immunostaining following 737 
incubation for 4 d (WT and Min NS1) and 7 d (Min E and Min E+NS1) under 738 
methylcellulose at 37 °C, respectively. Data shown (a, b, c, d, e and f) are the means and 739 
standard deviations (mean ± SD) analyzed by Student’s t test (two tailed, *, P < 0.05; **, 740 
P < 0.01; ***, P < 0.001).   741 
Fig 3. IFA of E protein expression in Vero cells infected with WT or codon pair-742 
deoptimized ZIKVs. 743 
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Vero cells were infected with viruses at an moi of 0.01. On 2, 3 and 4 dpi, IFA was 744 
performed as described in Materials and Methods. All the images were captured at 745 
10×magnification. Green represents E protein and blue represents nuclei (stained with 746 
Hoechst 33258). 747 
Fig 4. Attenuation of codon pair-deoptimized ZIKVs in AG6 mice 748 
Groups of AG6 mice (3-to-4-week-old, n = 6) were infected intraperitoneally with 102 749 
IFU of WT or codon pair-deoptimized ZIKVs, respectively. Body weight loss (A) and 750 
survival (B) were monitored daily for 4 weeks. Mice were euthanized when they lost 25% 751 
of their initial body weight.   752 
Fig 5. Immunohistochemical staining of E protein in brain sections from infected 753 
mice.  754 
AG6 mice were infected with 102 IFU of viruses (n=3). The brain tissues from mice 755 
infected with WT virus were collected at 7 dpi. The brain tissues from mice infected with 756 
Min E+NS1 were collected at 28 dpi.  757 
Fig 6. Viral loads in organs or sera of infected AG6 mice.  758 
Mice (n = 3) were infected with 102 IFU of viruses, euthanized at day 3, day 6, or day 7, 759 
and organ viral loads were determined at day 3 and day 7 by qRT-PCR (A) and 760 
Immunostaining focus assay (spleen；B). Serum viral loads were determined at day 3 761 
and day 6 by qRT-PCR (C). Data shown (a, b and c) are the means and standard 762 
deviations (mean ± SD) analyzed by Student’s t test (two tailed, *, P < 0.05; **, P < 0.01; 763 
***, P < 0.001).  764 
Fig 7. Humoral and cellular immune responses induced by codon pair-deoptimized 765 
ZIKVs in mice.  766 
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(A) Prechallenge neutralization antibody titers were measured on day 28 (day 7 for WT 767 
virus) after immunization using a standard PRNT50 assay. (B) Cellular immune responses 768 
were assessed on day 28 after immunization by IFN-γ ELISPOT assays. Data shown (a 769 
and b) are the means and standard deviations (mean ± SD) analyzed by Student’s t test 770 
(two tailed, **, P < 0.01).      771 
Fig 8. Protection efficacy of codon pair-deoptimized ZIKVs in mice.  772 
Mice were immunized with 102 IFU of codon pair-deoptimized viruses or mock 773 
vaccinated with PBS. At 4 weeks postvaccination, animals were challenged with 104 IFU 774 
of WT virus (an approximately 5500-fold MLD50). Body weight loss (A) and survival 775 
(B) were evaluated for 14 days after the challenge. Mice were euthanized when they lost 776 
25% of their initial body weight. (C) Postchallenge viremia was quantified by qRT-PCR 777 
on day 3 after challenge. (D) Postchallenge neutralization antibody titers were determined 778 
at day 14 after challenge by a standard PRNT50 assay. Data shown (c and d) are the 779 
means and standard deviations (mean ± SD) analyzed by Student’s t test (two tailed, *, P 780 
< 0.05; **, P < 0.01; ***, P < 0.001).   781 
Fig 9. Min E+NS1 immunization protected AG6 mice during pregnancy.  782 
(A) Scheme of immunization of 4-week-old AG6 female mice with 102 IFU of Min 783 
E+NS1 or PBS. (B-D) At day 32 post immunization, vaccinated female mice were mated 784 
with AG6 males. Pregnant mice (n = 4) were with 104 IFU of WT virus on E6. (B) 785 
Neutralization antibody titers were measured on day 1 before challenge using a standard 786 
PRNT50 assay. (C) Maternal viremia on day 2 after challenge was quantified by qRT-787 
PCR. (D) Outcome of fetuses from Min E+NS1 or PBS vaccinated dams. a All PBS-788 
immunized pregnant mice died without delivery. b Maternal neutralization antibody titers 789 
of pups delivered at term to Min E+NS1 vaccinated dams were measured at the 21th day 790 
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after birth. Data shown (b and c) are the means and standard deviations (mean ± SD) 791 
analyzed by Student’s t test (two tailed, ***, P < 0.001).    792 
 793 
Table legends 794 
Table 1. Characteristics of deoptimized ZIKV genome segments. 795 
Table 2. The increases of C3G1 and U3A1 in deoptimized ZIKV genome segments. 796 
Table 3. Median lethal dose (MLD50) values in AG6 mice after intraperitoneal 797 
inoculation. 798 
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Table 1. Characteristics of deoptimized ZIKV genome segments 
Virus Deoptimized 
coding region 
Human codon pair 
bias of wt segment 
Human codon pair 
bias of 
deoptimized 
segment 
Mosquito codon 
pair bias of wt 
segment 
Mosquito codon 
pair bias of 
deoptimized 
segment  
Number of silent 
mutations (total 
nucleic acids) 
Min E 1-1512 0.0336 -0.5741 -0.0099 -0.0729 363(1512) 
Min NS1 1-1056 0.0059 -0.5162 -0.0077 -0.0809 219(1056) 
Min E+NS1 1-2568 0.0222 -0.5503 -0.0090 -0.0764 582(2568) 
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Table 2. The increases of C3G1 and U3A1 in deoptimized ZIKV genome segments 
Gene Encoding Length, nt C3G1 ΔC3G1* U3A1 ΔU3A1* 
E WT 1512 20 — 14 — 
E deoptimized 1512 111 +91(455%) 66 +52(371%) 
NS1 WT 1056 17 — 13 — 
NS1 deoptimized 1056 67 +50(294%) 37 +24(185%) 
E+NS1 WT 2568 37 — 27 — 
E+NS1 deoptimized 2568 178 +141(381%) 103 +76(281%) 
*The number of CpGs and UpAs in deoptimized segments is added with respect to 
WT segments. 
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Table 3. Median lethal dose (MLD50) values in AG6 mice after intraperitoneal 1 
inoculation 2 
Virus MLD50 (no. of PFU/mouse) 
ZIKVwt 1.78 
Min E 1750.83 
Min NS1 2.98 
Min E+NS1 3981.07 
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